Understanding the scientific literature (Reading and evaluation of a research paper) Prof David Lane Department of Haematology Hammersmith Hospital Campus.

Slides:



Advertisements
Similar presentations
Venous Thrombo-embolism In Pregnancy
Advertisements

Venous Thromboembolism: Risk Assessment and Prophylaxis
Anti-Phospholipid Antibody Syndrome The Annexin A5 Competition Assay as a Diagnostic Tool.
Indications for a thrombophilia workup in Obstetrics Helen H. Kay, MD February, 2005.
1 THROMBOPHILIA. 2 Thrombophilia is technical term for hypercoagulable state Thrombosis (arterial or venous) is produced by a shift in the balance between.
Venous thromboembolism –
Thrombophilia. Now considered a multicausal disease, with an interplay of acquired and genetic thrombotic risk factors Approximately half of venous thromboembolic.
Pathology of Coagulation I- Deficiency of Coagulation Factors II- II- HYPERCOAGULABLE STATES.
Thrombophilic states. Thrombophilic state is characterized by a shift in the coagulation balance in favour of hypercoagulability – i.e. easier and oftener.
Pathology 430/826 Thrombosis David Lillicrap. Cardiovascular Disease 30% of all deaths in Canada 54% ischemic heart disease 20% stroke 23% heart attack.
The DASH Study Patrick Leonberger MSIV BGSMC Nov 8, 2013.
Factor V Leiden Developed by Dr. Judith Allanson, Ms. Shawna Morrison and Dr. June Carroll Last updated Dec 2014.
Clinical Genetics M. Kent Froberg, MD Purpose This lecture is designed to illustrate two examples of the use of molecular genetics in the clinical.
Dr msaiem Acquired Coagulation Disorders Dr Mohammed Saiem Al-dahr KAAU Faculty of Applied Medical Sciences.
Below the Knee DVT and Pregnancy Related Thrombosis Robert Lampman, MD Morning Report July 2009.
Week 7: Fibrinolysis and Thrombophilia Secondary fibrinolysis Secondary fibrinolysis Primary fibrinolysis Primary fibrinolysis Plasminogen Plasminogen.
Venous thromboembolism: how long to treat?
Deep vein thrombosis. Color duplex scan of DVT Venogram shows DVT.
Thrombophilias Sharon Sams. Objectives Overview of etiology of hypercoagulability Available tests Clinical correlation or “What do I do with these results?”
PATHOPHYSIOLOGY OF THROMBOSIS “Virchow’s Triad” 1.Injury to blood vessels Trauma, atherosclerosis, surgery 2.Stasis of blood Immobility, venous incompetence,
Dr Nico Lategan MBChB, MMed (Haematology)
Hypercoagulable States Basic Clinician Training Module 4 Introduction Hypercoagulable States Test Your Knowledge.
Extended Anticoagulation in VTE Geoffrey Barnes, MD Cardiovascular and Vascular Medicine University of Michigan, USA 1 st Qatar Conference on Safe Anticoagulation.
Chapter Ten Venous Disease Coalition Hypercoagulability VTE Toolkit.
Thrombophilia— Hypercoagulable States Gabriel Shapiro, MD, FACP.
Bob Silver, MD University of Utah Health Sciences Thrombophilias in Obstetrics Modified from a presentation to the Society of Maternal Fetal Medicine by.
Supervisor: Vs 余垣斌 Presenter: CR 周益聖. INTRODUCTION.
APPROACH TO BLEEDING DISORDERS. History of Bleeding Spontaneous vs. trauma/surgery-induced Ecchymoses without known trauma Medications or nutritional.
DEFINING THE DURATION OF ANTICOAGULATION. HOW LONG TO TREAT A DVT?
THROMBOTIC COMPLICATIONS OF PANREATIC CANCER: A CLASSICAL KNOWLEDGE REVISITED D. L. DUMITRASCU, O. SUCIU, C. GRAD, D. GHEBAN 2 ND MEDICAL DEPT. UMPh IULIU.
Oral Rivaroxaban for Symptomatic Venous Thrombroenbolism Group /06/11.
Hypercoagulable Syndromes. Risk Factors For Venous Thrombosis ACQUIREDINHERITEDMIXED/UNKNOWN Advancing ageAntithrombin Deficiency  Homocysteine ObesityProtein.
Thrombophilia=Tendency to Thrombosis HEREDITARYACQUIRED.
Pulmonary Embolism Treatment in Cancer - Is It Different 34th Brazilian Thoracic Conference 6th ALAT Congress 5th Brazil-Portugal Congress Brazilia/DF.
Tabuk University Faculty of Applied Medical Sciences Department Of Medical Lab. Technology 3 rd Year – Level 5 – AY
Thrombophilia National Haemophilia Director
Antiplatelet Therapy Use and the Risk of Venous Thromboembolic Events in the Double-Blind Raloxifene Use for the Heart (RUTH) Trial C. Duvernoy 1, A. Yeo.
Thrombophilia (Hypercoagulable States) Abdulkareem Almomen, MD Professor of Medicine & Hematology, King Saud University MED 341, Feb.2014.
Thrombophilia. Definition –Tendency to develop clots due to predisposing factors that may be genetically determined.
Charles J. Lockwood, M.D. The Anita O’Keefe Young Professor and Chair Department of Obstetrics, Gynecology and Reproductive Sciences Yale University School.
A Randomized Trial of Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism Schulman S et al. Proc ASH 2011;Abstract 205.
Venous thromboembolic disease
Higher Incidence of Venous Thromboembolism (VTE) in the Outpatient versus Inpatient Setting Among Patients with Cancer in the United States Khorana A et.
Protein C.  Protein C is a major physiological anticoagulant. anticoagulant  It is a vitamin K-dependent serine protease enzyme, that is activated by.
Inherited Thrombophilia is Associated with:
LABORATORY DIAGNOSIS OF PROTHROMBOTIC STATES. REGULATION OF COAGULATION Introduction Coagulation necessary for maintenance of vascular integrity Enough.
Thrombophilia Made Simple for Obstetricians
Oral, Direct Factor Xa Inhibition with Rivaroxaban for the Prevention of Venous Thromboembolism After Total Hip Replacement Eriksson BI, Borris L, Dahl.
Thrombosis and Haemostasis Café Cardiologique 29/10/2014.
Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation NEJM Aug 27, 2015.
Deficiencies of Proteins C, S and Antithrombin and Activated Protein C Resistance – Their Involvement in the Occurrence of Arterial Thromboses Report PGY.
Factor V Leiden Developed by Dr. Judith Allanson, Ms. Shawna Morrison and Dr. June Carroll Last updated Dec 2014.
Venous Thromboembolism-1
Venous thrombosis , why should I care ?
HAEMOSTASIS AND THROMBOSIS Regulation of coagulation
Thrombosis.
Hypercoagulable States
Discounted Coagulation Profiles Clinical Laboratories.
Oral Anticoagulation and Preventing Stent Thrombosis
Extended Treatment of VTE: Who is the Right Candidate?
Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with.
The γ-carboxyglutamic acid domain of anticoagulant protein S is involved in activated protein C cofactor activity, independently of phospholipid binding.
Selective testing for thrombophilia in patients with first venous thrombosis: results from a retrospective family cohort study on absolute thrombotic risk.
Figure 1 The coagulation system
 INDICATIONS AND USAGE  DOSAGE AND ADMINISTRATION  DOSAGE FORMS AND STRENGTHS  WARNINGS AND PRECAUTIONS  ADVERSE REACTIONS  USE IN SPECIFIC POPULATIONS.
Thrombophilia.
Ted Wun, M. D. , Ann Brunson, M. S. , Theresa Keegan, Ph. D
Davide Capodanno et al. JCIN 2009;2:
Factor VIIa interaction with EPCR modulates the hemostatic effect of rFVIIa in hemophilia therapy: mode of its action by Shiva Keshava, Jagan Sundaram,
Hemostasis and Coagulation
Presentation transcript:

Understanding the scientific literature (Reading and evaluation of a research paper) Prof David Lane Department of Haematology Hammersmith Hospital Campus

Our paper is: Risk factors and recurrence rate of primary deep vein thrombosis of the upper extremities. Martinelli et al, Circulation 2004; 110: (This is given to you initially without the Title and Abstract. The Abstract will be given out at the end)

Aims of the paper are: 1. Investigate the role of risk factors (thrombophilia, transient) in upper extremity DVT. 2. To evaluate recurrence rate after a period of antcoagulant therapy. It uses a case control study design.

Haemostasis is a fine balance between procoagulant and anticoagulant activities Inadequate procoagulant/excessive anticoagulant function - bleeding Lo Pro Coag Thrombosis Bleeding Hi Anti Coag

Haemostasis is a fine balance between procoagulant and anticoagulant activities Excessive procoagulant/inadequate anticoagulant function - thrombosis Hi Pro Coag Thrombosis Bleeding Lo Anti Coag

+ + FVIII FV Procoagulant FibrinFibrinogen ProthrombinThrombin FVa FX FXa FVIIIa FIXa End Stage Blood Coagulation TF/FVIIa

Coagulation Inhibitory Mechanisms 1.Antithrombin (+heparin or heparan sulphate) 2.Protein C anticoagulation pathway 3.Tissue factor pathway inhibitor 1 & 2 are of know clinical importance! 3 is important physiologically, but of uncertain clinical importance!

+ + FVIII FV Procoagulant FibrinFibrinogen ProthrombinThrombin FVa FX FXa FVIIIa FIXa Thrombin-Antithrombin Complex FXa-Antithrombin Complex Antithrombin + Heparin or EC Heparan Sulphate Anticoagulant Coagulation Regulation By Antithrombin

+ + FVIII FV FVIIIi FVi Procoagulant Protein Ca (APC) Protein C/EPCR Protein S Anticoagulant Thrombomodulin FibrinFibrinogen ProthrombinThrombin FVa FX FXa FVIIIa FIXa Coagulation Regulation by Activated Protein C

Factor Va Model of factor Va Pellequer et al Thromb Haemost 2000;84,849 APC cleavage sites in FVa

Inactivation of Factor Va By APC BIPHASIC INACTIVATION Arg306 “Slow” cleavage Completely abolishes FVa activity Arg506 “Rapid” cleavage Results in FVa with intermediate (25%-40%) co-factor activity

Factor V Leiden (Arg506Gln) FV Leiden (Arg506Gln) -mutation/polymorhism present in ~5% of white Caucasians -associated with “APC-resistance” -most prevalent genetic thrombophiliac factor in people of European descent Arg506Gln Arg->Gln substitution prevents proteolysis by APC at 506 site. FVa is therefore only partially inactivated

5’3’ I IIXIV Organisation of Prothrombin Gene chromosome 11p11-q12 ~21kb G/A, increases prothrombin levels, increase risk of DVT X Catalytic domain VVII Kringles Leader + Gla (Degan & Davie Biochemistry , 1987 Poort et al Blood )

Some risk factors for venous thromboembolism Genetic (thrombophilia) risk factors Antithrombin deficiency* Protein C deficiency* Protein S deficiency* Factor V Leiden* Prothrombin G20210A* Acquired/acquired risk factors Hyperhomocysteinemia* Antiphospholipid antibodies Transient risk factors Oral contraceptives* Travel Surgery HRT Pregnancy *of interest today

Risk Age Thrombotic threshold Risk from “ageing” Genetic risk 2 Genetic risk 1 Venous Thrombosis is Multi-Causal Arising from Interacting Genetic and Acquired Risk Factors Cumulative risk Transient acquired risk after Rosendaal, 1998

Odds Ratio Odds of an event Number of events/number of non events Odds ratio Odds in treated or exposed group/odds in control group

Odds Ratio In a week 90/100 men have drunk beer Odds 90/10 20/100 women have drunk beer Odds 20/80 Odds Ratio 90/10 = 36 20/80

95% Confidence Interval (CI) A 95% confidence interval is an interval generated by a process that is correct 95% of the time. It gives a measure of confidence to the mean. If 95% CI crosses unity, result not “statistically” significant! Compare OR (95% CI) 3.3 ( ) With3.2 ( ) (taken from Table 1 of paper)

Relative risk is another common measure of risk. RR= Probability of event in exposed group Probability of event in non exposed group RR is actually very similar to Odds Ratio, especially when the probabilities are small. In Clinical Studies, the Odds Ratio is favoured for case control studies and retrospective studies. Relative Risk is used in randomised controlled trials and cohort studies. Relative Risk

Example of OR calculation: Factor V Leiden 10/105= /775 (The adjusted results in last column are to be focussed on)

Example of OR calculation: Compare results in last and first lines 5/35= /191 (Results in final column, adjusted for age, are the ones to focus on)

Kaplan Meier plots and Hazard Ratios Kaplan Meier plots show survival (often expressed as % or as fraction of 1.00) over time Hazard ratio is broadly similar to Relative Risk. It is useful when the risk varies over time. The term is often used in connection with the Kaplan Meier survival plot (over time). If the overall RR of an event is half in one group, then HR is 0.5.

Prob of no recurrence at 5 years: Without thrombophilia 93% With thrombophilia 80% The adjusted Hazard Ratio for recurrence of upper limb DVT in patients with compared to those without thrombophilia is 2.7 (95% CI ): note this is not significant!

Task: In 60 minutes write a word abstract of the article. Divide the article into the following sections (section headings not to be included in the word count): Background Methods & Participants Results Conclusions Execution: Include size of study in Methods, and important findings in Results, expressed in quantitative terms.